Adrenal gland dysfunction and hypothalamus-pituitary-adrenal (HPA) axis dissociation
are common problems in patients with sepsis. Previously, we demonstrated that endothelial
dysfunction may actively participate in inflammation-related adrenal insufficiency.
We focused on developmental endothelial locus-1 (Del-1), an endothelial-derived anti-inflammatory
factor; because we found that its expression is strongly downregulated upon systemic
inflammation in the adrenal gland. Interestingly, we found that during Systemic Inflammatory
Response Syndrome (SIRS), Del-1 deficiency resulted in an elevated inflammation, leukocyte
accumulation and higher apoptosis in the adrenal glands, which was associated with
decreased corticosterone and adrenocorticotropic hormone levels 24h post LPS-administration.
These data indicated that Del-1 acts as a gatekeeper of adrenal gland inflammation
and thereby of adrenal function in the course of SIRS. However, the mechanisms involved
in the LPS-mediated downregulation of Del-1 in the adrenal gland remain unknown. Here
we showed that interleukin-17A (IL-17A) specifically downregulate endothelial Del-1
expression. Interestingly, we found that both IL-17A and its receptor IL-17RA are
induced in the adrenal gland in the course of SIRS. Along the same line, IL-17RA-deficient
mice displayed increased corticosterone but not ACTH secretion during LPS-mediated
SIRS. We currently pursue the hypothesis that the IL-17/IL-17R axis is a negative
regulator in adrenal dysfunction by downregulating Del-1 and promoting adrenal inflammation.